Drug Type Prophylactic vaccine |
Synonyms adjuvanted trivalent influenza vaccine, Influenza virus surface antigens (haemagglutinin and neuraminidase) of the following strains: A/(H1N1), A/(H3N2), B/Yamagata lineage, B/Victoria lineage, Aujemflu |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date European Union (20 Aug 2026), |
Regulation- |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Influenza, Human | European Union | 20 Aug 2026 | |
| Influenza, Human | Iceland | 20 Aug 2026 | |
| Influenza, Human | Liechtenstein | 20 Aug 2026 | |
| Influenza, Human | Norway | 20 Aug 2026 |





